It was interesting reading your opinion on Solbec and I concur...

It was interesting reading your opinion on Solbec and I concur with most of it . except the example of Milleniums drug Velcade as a comparison to SBP002 . That drug was for multiple myeloma , and results were not very impressive . Multiple myeloma already had a standard treatment recognised by the FDA . It was given orphan drug status and approved for limited use while phase 3 trials progressed . It was approved in March this year and phase 3 trials have already finished early . SBP002 has been getting great results , up to eradication of untreatable tumors . The FDA does not yet recognise any standard treatments for mesothelioma , one of the cancers SBP002 is targeting . With results like this a more relevent comparison would be the Novartis orphan drug Gleevec which was approved in 9 weeks after showing great results against leukemia . It was approved in May 2001 and is now available in 60 countries , including the US , Britain , Japan and Australia with sales over $US400 Million. Phase three studies have still not been completed on this drug . Like Novartis , Solbec has already set up to manufacture the drug . The clinical trials have already started . Professor Michael Millward , in charge of the trials was on the radio in Perth yesterday and stated he was very excited with the prospects . Look at the price and consider the potential .